Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 199

1.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

2.

DNA methylation-based reclassification of olfactory neuroblastoma.

Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S, Koelsche C, Schrimpf D, Niesen J, Wefers AK, Jones DTW, Sill M, Weigert O, Ligon KL, Olar A, Koch A, Forster M, Moran S, Tirado OM, Sáinz-Japeado M, Mora J, Esteller M, Alonso J, Del Muro XG, Paulus W, Felsberg J, Reifenberger G, Glatzel M, Frank S, Monoranu CM, Lund VJ, von Deimling A, Pfister S, Buslei R, Ribbat-Idel J, Perner S, Gudziol V, Meinhardt M, Schüller U.

Acta Neuropathol. 2018 May 5. doi: 10.1007/s00401-018-1854-7. [Epub ahead of print]

PMID:
29730775
3.

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.

Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, Sopper S, Rieder D, Krogsdam A, Gamerith G, Perner S, Tzankov A, Trajanoski Z, Wolf D, Baier G.

Nat Commun. 2018 Apr 18;9(1):1538. doi: 10.1038/s41467-018-04004-2.

4.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK.

Nat Commun. 2018 Mar 13;9(1):1048. doi: 10.1038/s41467-018-03099-x.

5.

In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.

Krupar R, Schreiber C, Offermann A, Lengerke C, Sikora AG, Thorns C, Perner S.

Leuk Lymphoma. 2018 Feb 12:1-4. doi: 10.1080/10428194.2018.1434883. [Epub ahead of print] No abstract available.

PMID:
29431550
6.

Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.

Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, Müller SC, Ellinger J.

Clin Epigenetics. 2018 Jan 23;10:11. doi: 10.1186/s13148-018-0444-9. eCollection 2018.

7.

Epigenetic modifications of the VGF gene in human non-small cell lung cancer tissues pave the way towards enhanced expression.

Marwitz S, Heinbockel L, Scheufele S, Nitschkowski D, Kugler C, Perner S, Reck M, Ammerpohl O, Goldmann T.

Clin Epigenetics. 2017 Nov 28;9:123. doi: 10.1186/s13148-017-0423-6. eCollection 2017.

8.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.

Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

PMID:
29198908
9.

Effect of Antigen Retrieval Methods on Nonspecific Binding of Antibody-Metal Nanoparticle Conjugates on Formalin-Fixed Paraffin-Embedded Tissue.

Zhang Y, Wang XP, Perner S, Bankfalvi A, Schlücker S.

Anal Chem. 2018 Jan 2;90(1):760-768. doi: 10.1021/acs.analchem.7b03144. Epub 2017 Dec 11.

PMID:
29148719
10.

[Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].

Hupe MC, Offermann A, Perabo F, Chandhasin C, Perner S, Merseburger AS, Cronauer MV.

Urologe A. 2018 Feb;57(2):148-154. doi: 10.1007/s00120-017-0541-y. Review. German.

PMID:
29147733
11.

Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.

Krupar R, Hautmann MG, Pathak RR, Varier I, McLaren C, Gaag D, Hellerbrand C, Evert M, Laban S, Idel C, Sandulache V, Perner S, Bosserhoff AK, Sikora AG.

Am J Pathol. 2018 Jan;188(1):72-83. doi: 10.1016/j.ajpath.2017.09.013. Epub 2017 Oct 27.

PMID:
29107073
12.

Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features.

Bissinger O, Götz C, Kolk A, Bier HA, Agaimy A, Frenzel H, Perner S, Ribbat-Idel J, Wolff KD, Weichert W, Mogler C.

Rare Tumors. 2017 Oct 3;9(3):7162. doi: 10.4081/rt.2017.7162. eCollection 2017 Oct 3.

13.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

14.

IL-4/5 signalling plays an important role during Litomosoides sigmodontis infection, influencing both immune system regulation and tissue pathology in the thoracic cavity.

Ritter M, Tamadaho RS, Feid J, Vogel W, Wiszniewsky K, Perner S, Hoerauf A, Layland LE.

Int J Parasitol. 2017 Dec;47(14):951-960. doi: 10.1016/j.ijpara.2017.06.009. Epub 2017 Aug 30.

15.

Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.

Schecher S, Walter B, Falkenstein M, Macher-Goeppinger S, Stenzel P, Krümpelmann K, Hadaschik B, Perner S, Kristiansen G, Duensing S, Roth W, Tagscherer KE.

Int J Cancer. 2017 Oct 15;141(8):1643-1653. doi: 10.1002/ijc.30864. Epub 2017 Jul 12.

PMID:
28670704
16.

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression.

Marwitz S, Scheufele S, Perner S, Reck M, Ammerpohl O, Goldmann T.

Clin Epigenetics. 2017 May 11;9:51. doi: 10.1186/s13148-017-0354-2. eCollection 2017.

17.

Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression.

Klümper N, Syring I, Vogel W, Schmidt D, Müller SC, Ellinger J, Shaikhibrahim Z, Brägelmann J, Perner S.

Front Med (Lausanne). 2017 Mar 17;4:30. doi: 10.3389/fmed.2017.00030. eCollection 2017.

18.

ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.

Schmitt A, Knittel G, Welcker D, Yang TP, George J, Nowak M, Leeser U, Büttner R, Perner S, Peifer M, Reinhardt HC.

Cancer Res. 2017 Jun 1;77(11):3040-3056. doi: 10.1158/0008-5472.CAN-16-3398. Epub 2017 Mar 31.

19.

Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.

Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, Fehm TN, Kanz L, Schulze-Osthoff K, Lengerke C.

Cancer Res. 2017 Apr 15;77(8):2148-2160. doi: 10.1158/0008-5472.CAN-16-0593. Epub 2017 Feb 16.

20.

MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.

Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R, Gnjatic S, Krupar R, Sikora AG, Litjens G, Grabe N, Kristiansen G, Bootz F, Schuler PJ, Brunner C, Brägelmann J, Hoffmann TK, Perner S.

Oncotarget. 2017 Feb 28;8(9):14719-14735. doi: 10.18632/oncotarget.14830.

Supplemental Content

Loading ...
Support Center